Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06460038 · ClinicalTrials.gov registry record · Phase 2
Tenapanor in Synucleinopathy-Related Constipation
A Phase 2 study of Parkinson's Disease and Synucleinopathy, sponsored by Cedar Valley Digestive Health Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
- 1
- Study location
NCT06460038 is a Phase 2 study of Parkinson's Disease and Synucleinopathy that is actively recruiting participants, run by Cedar Valley Digestive Health Center. The registered enrollment target is 30 participants, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT06460038, a Phase 2 study of Parkinson's Disease and Synucleinopathy, is actively recruiting participants, sponsored by Cedar Valley Digestive Health Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
- 1
- Study location
Study Summary
Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Tenapanor
Study Locations (1)
Iowa
- Cedar Valley Digestive Health Center - Waterloo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2025-01-01 |
| Est. Completion | 2027-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06460038
The ClinicalTrials.gov registry entry for NCT06460038 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 642-participant average among 156 other Parkinson's Disease trials with a reported enrollment target (95% lower). The listed sponsor is Cedar Valley Digestive Health Center, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Parkinson's Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06460038 reports 1 study location spanning 1 distinct geographic area - top geographies include Iowa.
Frequently Asked Questions
What is clinical trial NCT06460038 about?
NCT06460038 is a clinical study titled "Tenapanor in Synucleinopathy-Related Constipation". Investigation of tenapanor as a potential treatment for synucleinopathy-associated constipation
What is the current status of trial NCT06460038?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2025-01-01. Estimated completion is 2027-03.
What conditions does trial NCT06460038 study?
This clinical trial studies the following conditions: Parkinson's Disease, Synucleinopathy.
What interventions are being tested in trial NCT06460038?
The interventions under investigation include: Placebo (DRUG), Tenapanor (DRUG).
Who is sponsoring clinical trial NCT06460038?
This trial is sponsored by Cedar Valley Digestive Health Center, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06460038 being conducted?
This trial has 1 study location across Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson's Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Ketamine for Veterans With Parkinson's Disease
RECRUITING · Phase 2
-
Imaging Depression in Parkinson's Disease
RECRUITING · Phase 2
-
Evaluation of Tau-Pathology in Sporadic and LRRK2 Parkinson's Disease
RECRUITING · Phase 2
-
A Long Term Safety Study of ND0612 Administered as a Continuous SC Infusion in Advanced Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
A Study to Evaluate the Efficacy of Prasinezumab (RO7046015/PRX002) in Participants With Early Parkinson's Disease
ACTIVE NOT RECRUITING · Phase 2
-
Efficacy, Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of BIA 28-6156 in GBA-PD
ACTIVE NOT RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.